Dr Reddys Laboratories announced that its subsidiary, Promius Pharma LLC has filed a lawsuit for patent infringement in the United States District Court for Eastern District of Texas against Perrigo UK FINCO Limited Partnership, Perrigo Israel Pharmaceuticals, and
Taro Pharmaceuticals, Inc. in response to two paragraph-IV notice letters received for its twice daily topical spray SERNIVO (betamethasone dipropionate, 0.05%) product. Promius anticipates this lawsuit will trigger a 30 month stay of FDA approval of Perrigo's and Taro's ANDAs.
SERNIVO spray, 0.05% is protected by six Orange Book patents that expire in 2030. Promius will continue to vigorously defend its SERNIVO intellectual property rights against infringement wherever they are challenged
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
